The FDA issued warning letters to several websites marketing magnetic stimulation devices directly to consumers without a prescription. The letters specifically address devices marketed for "depression," "anxiety," "focus," and similar indications that fall under the agency's medical device authority.
The warnings emphasize that FDA-cleared TMS devices for depression and OCD are prescription-only and require physician supervision, motor threshold determination, and a defined treatment protocol. Consumer devices marketed for these indications without clearance create risks ranging from ineffective treatment to seizure.
The FDA also clarified that low-intensity magnetic stimulation devices marketed under wellness or general fitness claims do not necessarily fall under medical device authority but may not legally make therapeutic claims.
The Clinical TMS Society endorsed the FDA action. The Society has previously raised concerns about consumer confusion between FDA-cleared TMS and lower-intensity wellness devices, and has called for clearer labeling guidance from the agency.
Source
Reporting based on coverage from FDA Newsroom. This article is editorial summary intended for general information; it is not medical advice.